神経治療学
Online ISSN : 2189-7824
Print ISSN : 0916-8443
ISSN-L : 2189-7824
特集 神経疾患治療の進歩 2018
認知症の治療の進歩
丹羽 篤冨本 秀和
著者情報
ジャーナル フリー

2019 年 36 巻 5 号 p. 569-572

詳細
抄録

Dementia affects over 46 million people in the world with a rapidly increasing prevalence. No fundamental treatment for AD has been established, and novel experimental studies are under investigation. This progress has led to the development of numerous therapeutic strategies in the clinical testing. Immunotherapy against Aβ has been pursued extensively as a therapeutic approach to AD and other dementias, and several other promising trials are currently ongoing.

In 2018, these outcomes including solanezumab, verubecestat, LMTM, idalopirdine, pimavanserin and so on have been reported. This review overviewed recent advances in these larger clinical researches in dementia.

著者関連情報
© 2019 日本神経治療学会
前の記事 次の記事
feedback
Top